Trial Profile

A phase I/II study of nab-paclitaxel (Abraxane) and gemcitabine followed by modified FOLFOX (AG-mFOLFOX) in patients with previously untreated, metastatic pancreatic adenocarcinoma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 05 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary) ; Fluorouracil; Folinic acid; Folinic acid; Gemcitabine; Oxaliplatin
Indications Adenocarcinoma; Pancreatic cancer
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms SEQUENCE

07 Jun 2022 Primary endpoint has been met (Phase II: Overall survival al 12 months after treatment initiation) , according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
07 Jun 2022 Results (n=157) reporting safety profile and clinical activity from phase II portion of this trial presented at the 58th Annual Meeting of the American Society of Clinical Oncology
11 Aug 2021 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com